Ana Sofia Correia

1.4k total citations
29 papers, 989 citations indexed

About

Ana Sofia Correia is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Neurology. According to data from OpenAlex, Ana Sofia Correia has authored 29 papers receiving a total of 989 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Pathology and Forensic Medicine and 6 papers in Neurology. Recurrent topics in Ana Sofia Correia's work include Multiple Sclerosis Research Studies (8 papers), Pluripotent Stem Cells Research (7 papers) and Autoimmune and Inflammatory Disorders Research (3 papers). Ana Sofia Correia is often cited by papers focused on Multiple Sclerosis Research Studies (8 papers), Pluripotent Stem Cells Research (7 papers) and Autoimmune and Inflammatory Disorders Research (3 papers). Ana Sofia Correia collaborates with scholars based in Portugal, Sweden and Canada. Ana Sofia Correia's co-authors include Sergey V. Anisimov, Jiayi Li, Asuka Morizane, Jean‐Pierre Julien, Priyanka Patel, Kallol Dutta, Rong Wang, Fumiko Shimizu, Koos E. Hovinga and Maartje van der Heijden and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Neurology.

In The Last Decade

Ana Sofia Correia

27 papers receiving 973 citations

Peers

Ana Sofia Correia
Hyesook Yoon United States
Nathalie Kertesz United States
George H. De Vries United States
Hyesook Yoon United States
Ana Sofia Correia
Citations per year, relative to Ana Sofia Correia Ana Sofia Correia (= 1×) peers Hyesook Yoon

Countries citing papers authored by Ana Sofia Correia

Since Specialization
Citations

This map shows the geographic impact of Ana Sofia Correia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Sofia Correia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Sofia Correia more than expected).

Fields of papers citing papers by Ana Sofia Correia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Sofia Correia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Sofia Correia. The network helps show where Ana Sofia Correia may publish in the future.

Co-authorship network of co-authors of Ana Sofia Correia

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Sofia Correia. A scholar is included among the top collaborators of Ana Sofia Correia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Sofia Correia. Ana Sofia Correia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Salavisa, Manuel, et al.. (2023). Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression. Clinical Neurology and Neurosurgery. 225. 107612–107612. 9 indexed citations
2.
Correia, Ana Sofia, Tiago Morais, Ana D. Martins, et al.. (2022). Obesity-Related Genes Expression in Testes and Sperm Parameters Respond to GLP-1 and Caloric Restriction. Biomedicines. 10(10). 2609–2609. 6 indexed citations
3.
Carvalho, Vanessa, Joaquim Pinheiro, Inês Brás Marques, et al.. (2021). RISCOP–Cognitive profile in a Portuguese cohort of radiological isolated syndrome patients: A case-control study. Multiple Sclerosis and Related Disorders. 50. 102832–102832. 1 indexed citations
4.
Palavra, Filipe, et al.. (2021). TyPed study: Natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal. Multiple Sclerosis and Related Disorders. 51. 102865–102865. 14 indexed citations
5.
Marto, João Pedro, et al.. (2020). Anabolic Androgenic Steroid Abuse and Cerebral Venous Thrombosis—A Case Report. 16(2). 120–120.
6.
Salavisa, Manuel, et al.. (2020). Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse. Journal of Neuroimmunology. 347. 577355–577355. 15 indexed citations
7.
Batista, Sónia, Carla Nunes, João Cerqueira, et al.. (2020). REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal. Neurological Sciences. 42(5). 1995–2003. 5 indexed citations
8.
Foveau, Bénédicte, Ana Sofia Correia, Sébastien S. Hébert, et al.. (2019). Stem Cell-Derived Neurons as Cellular Models of Sporadic Alzheimer’s Disease. Journal of Alzheimer s Disease. 67(3). 893–910. 14 indexed citations
9.
Ladeira, Filipa, Ana Sofia Correia, Ana Silva, et al.. (2019). A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal. Clinical Neurology and Neurosurgery. 184. 105390–105390. 4 indexed citations
10.
Ladeira, Filipa, et al.. (2018). The Influence of Menopause in Multiple Sclerosis Course: A Longitudinal Cohort Study. European Neurology. 80(3-4). 223–227. 29 indexed citations
11.
Ladeira, Filipa, Marcelo Mendonça, André Caetano, et al.. (2018). Effect of patients’ expectations on clinical response to fampridine treatment. Neurological Sciences. 40(1). 175–180. 3 indexed citations
12.
Correia, Ana Sofia, Priyanka Patel, Kallol Dutta, & Jean‐Pierre Julien. (2015). Inflammation Induces TDP-43 Mislocalization and Aggregation. PLoS ONE. 10(10). e0140248–e0140248. 86 indexed citations
13.
Correia, Ana Sofia, et al.. (2015). A sporadic case of late-onset familial amyloid polyneuropathy with a monoclonal gammopathy. Neuromuscular Disorders. 25(8). 658–660. 3 indexed citations
14.
Mendonça, Marcelo, et al.. (2014). Spinal Cord Infarction and Patent Foramen Ovale: Is There a Link. Case Reports in Neurology. 6(2). 188–192.
15.
Alves, Luísa, Ana Sofia Correia, Rita Miguel, Paulo Alegria, & Paulo Bugalho. (2012). Alzheimer’s Disease: A Clinical Practice-Oriented Review. Frontiers in Neurology. 3. 63–63. 49 indexed citations
16.
Anisimov, Sergey V., Nicolaj S. Christophersen, Ana Sofia Correia, et al.. (2010). Identification of molecules derived from human fibroblast feeder cells that support the proliferation of human embryonic stem cells. Cellular & Molecular Biology Letters. 16(1). 79–88. 15 indexed citations
17.
Anisimov, Sergey V., Asuka Morizane, & Ana Sofia Correia. (2010). Risks and Mechanisms of Oncological Disease Following Stem Cell Transplantation. Stem Cell Reviews and Reports. 6(3). 411–424. 20 indexed citations
18.
Correia, Ana Sofia. (2007). Fibroblast growth factor-20 increases the yield of midbrain dopaminergic neurons derived from human embryonic stem cells. Frontiers in Neuroanatomy. 1. 4–4. 22 indexed citations
19.
Anisimov, Sergey V., Nicolaj S. Christophersen, Ana Sofia Correia, Jiayi Li, & Patrik Brundin. (2007). "NeuroStem Chip": a novel highly specialized tool to study neural differentiation pathways in human stem cells. BMC Genomics. 8(1). 46–46. 13 indexed citations
20.
Correia, Ana Sofia, Sergey V. Anisimov, Jiayi Li, & Patrik Brundin. (2005). Stem cell‐based therapy for Parkinson's disease. Annals of Medicine. 37(7). 487–498. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026